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THERE ARE THREE COMMON polymorphisms of apolipoprotein E: E2, E3, and E4. Compared with the most common E3 isoform, carriers of the E2 isoform have lower plasma cholesterols, whereas the opposite holds for carriers of the E4 isoform (4) . Genetic variation in apoE also influences plasma apoE concentrations, E2 Ͼ E3 Ͼ E4 (4) , and the plasma clearance of apoE, E4 Ͼ E3 Ͼ E2 (12, 13) , of chylomicron remnants, E4 Ն E3 Ͼ E2 (3, 25) , and of very low density lipoprotein (VLDL) and low-density lipoprotein (LDL) (8) . The evidence on how the E2 isoform influences lipid metabolism indicates that, compared with the E3 isoform, E2 is a poor ligand for the LDL receptor when incorporated into phospholipid complexes (26) and is less effective in mediating binding of lipoproteins to cell surface proteoglycans and to LDL-receptor-related protein (17, 26) . There is little comparable information on the E4 isoform despite its importance as a risk factor in coronary artery disease (27) . As indicated above, the influence of the E4 isoform on plasma cholesterol and lipoprotein clearance is opposite to that of the E2 isoform, suggesting that apoE4 might be associated with increased LDL-receptor binding. Although apoE4-and apoE3-containing synthetic phospholipid complexes were found to compete similarly against LDL for the LDL receptor (26) , these synthetic complexes might not reflect the binding of native lipoproteins. We decided therefore to test the hypothesis that inheritance of the E4 isoform increases the affinity of VLDL and LDL particles to the LDL receptor. The lipoproteins were isolated from apoE4 and -E3 homozygous subjects, and their affinity for the LDL receptor was studied in cultured fibroblasts and Hep G2 cells.
MATERIALS AND METHODS
Study subjects. Binding studies were carried out to determine the LDL-receptor affinities of VLDL and LDL isolated from eight pairs of E3/3 and E4/4 subjects who were matched as closely as possible in regard to age and serum lipid levels ( Table 1 ). The E3/3 and E4/4 subjects studied were aged 45 Ϯ 7 (SD) and 42 Ϯ 6 yr, respectively, and were Caucasian males who were not on any lipid-lowering therapy. The study was approved by the Ethics Committee of Royal Perth Hospital.
Blood collection and lipid and apolipoprotein analyses. After an overnight fast, blood was collected for isolation of LDL and VLDL, extraction of genomic DNA, and estimation of serum lipids. Serum total and high-density lipoprotein (HDL) cholesterol was measured enzymatically (Miles, Tarrytown, NY), with HDL cholesterol measured after precipitation of ␤-lipoproteins with dextran sulfate. LDL and VLDL protein was measured by the Lowry method as modified for lipoproteins (21) . Plasma and LDL apolipoprotein B (apoB) were measured by an immunonephelometric method on the Behring nephelometer, and VLDL apoB was estimated as isopropanol-insoluble VLDL protein (16) . ApoE genotyping was carried out on genomic DNA with the method of Hixson and Vernier (14) .
Isolation of lipoproteins. Blood was collected into 0.15% EDTA (final) and immediately centrifuged. Phenylmethylsulfonyl fluoride, gentamycin, and aprotinin were then added to final plasma concentrations of 1 mmol/l, 80 mg/l, and 10,000 U/l, respectively (9) . LDL was isolated by equilibrium density gradient ultracentrifugation as we have previously described (20) , dialyzed at 4°C against 250 volumes of 150 mmol/l NaCl, 10 mmol/l phosphate (PBS) containing 0.01% EDTA for 24 h, passed through a 0.45-µm filter, and stored under nitrogen at 4°C. VLDL was isolated by flotation ultracentrifugation at a density of 1.006 g/ml. Briefly, 5.5 ml of plasma was overlaid with 2.5 ml of a NaCl solution of density 1.006 g/ml containing 0.01% EDTA and was centrifuged in a Ti80 rotor at 50,000 rpm for 18 h at 20°C. VLDL was then removed from the top 1.0 ml. To ensure minimal contamination by lipoproteins of higher density, the VLDL was washed by a further centrifugation under the same conditions, dialyzed, and stored as described for LDL. In some experiments, VLDL-free plasma (VFP) comprised of the infranatant from the first centrifugation was also collected, dialyzed, and stored as described for LDL and VLDL.
Cell culture. Monolayer cultures of foreskin fibroblasts from a healthy male and Hep G2 cells were maintained in 75-cm 2 flasks with Dulbecco's modified Eagle's medium (DMEM, GIBCO, Grand Island, NY) supplemented with 10% fetal calf serum (GIBCO). For binding experiments, cells were grown to 75% confluence in 24-well plates, washed twice with PBS, and incubated in DMEM supplemented with lipoproteindeficient serum (LPDS) for 24-48 h to upregulate LDL receptors before binding studies. LPDS was prepared from fetal calf serum as described by Goldstein et al. (11) .
Radioiodination of LDL. LDL was labeled with 125 I by the iodine monochloride method as modified for lipoproteins by Bilheimer et al. (2) , and then it was immediately dialyzed and filtered as described above, stored at 4°C, and further dialyzed for 24 h just before binding studies. Studies on eight 125 I-LDL preparations showed that 92 Ϯ 3% of the radioactivity was associated with apoB, 98 Ϯ 2% with protein, and 2 Ϯ 1% with lipid as determined on isopropanol and trichloroacetic acid precipitates and chloroform extracts, respectively, of the radioiodinated LDL.
Binding studies. Conditions for binding studies were as previously described (21) . Cells were preincubated in assay buffer consisting of Eagle's minimal essential medium (ICN Biomedicals, Aurora, OH) containing 2.5 mmol/l HEPES, 42 mmol/l NaHCO 3 , and 4 mg/ml BSA (pH 7.4) for 20 min at 4°C. For each E4/4 and E3/3 pair studied, LDL from the E3/3 subject was radioiodinated as described previously (sp. act. 164 Ϯ 48 counts · min Ϫ1 · ng apoB Ϫ1 , n ϭ 8) and added to the medium at a final concentration of 10 µg apoB/ml, simultaneously with a range of concentrations of unlabeled test VLDL or LDL and incubated for 2 h at 4°C. Cells were then washed five times with ice-cold assay buffer and twice with ice-cold PBS containing 1.8 mmol/l CaCl 2 and 0.8 mmol/l MgSO 4 and then were solubilized by a 10-min incubation in 0.2 mol/l NaOH, and an aliquot was taken for gamma counting.
Data analysis and statistics. The concentrations of VLDL or LDL required to inhibit binding of 125 I-LDL to the LDL receptor by 50% (IC 50 ) were determined with a fourparameter logistic fitting equation on the RiaCalc program (LKB Wallac, Turku, Finland). Concentrations of VLDL and LDL are expressed in terms of their apoB content. Whereas individual IC 50 values are reported, the ratios of the IC 50 values for the pairs of E4/4 and E3/3 subjects are also reported and are more relevant for statistical purposes because this method of expression reduces the influence of interassay variability. Values are expressed as means Ϯ SD, and differences in values were compared with a two-tailed Student's t-test unless otherwise indicated. Table 1 shows the fasting serum lipid levels of the E4/4 and E3/3 subjects studied. Fasting serum cholesterol and triglycerides were above recommended levels but were within one standard deviation of the mean for male subjects of a similar age as reported for the Australian population (1989 National Heart Foundation of Australia Risk Factor Survey) and were similar for E3/3 and E4/4 subjects.
RESULTS
Direct binding studies on radiolabeled LDL from these subjects showed high-affinity binding in both of the cell types studied. For the LDL of eight E3/3 and eight E4/4 subjects, we found an overall dissociation constant (K d ) of 4.7 Ϯ 1.4 nmol/l in fibroblasts and for six E3/3 and six E4/4 subjects, 22 Ϯ 10 nmol/l in Hep G2 cells. We also found that VLDL could compete against LDL for this high-affinity binding. Figure 1 shows typical results for VLDL from a pair of E4/4 and E3/3 subjects competing against 125 I-LDL for binding to Hep G2 cells. Individual IC 50 values and IC 50 ratios in paired E4/4 and E3/3 subjects in both fibroblasts and Hep G2 cells are presented in Table 2 . IC 50 values are expressed, as outlined in the METHODS, in terms of micrograms apoB per milliliter. In Hep G2 cells, E4/4 
Values are means Ϯ SD. Chol, serum total cholesterol; Tg, serum triglycerides; HDL-C, serum high-density lipoprotein cholesterol. Fig. 1 . Competition of very low density lipoprotein (VLDL) from E3/3 (p) and E4/4 (s) subjects with 125 I-labeled low-density lipoprotein (LDL) for binding to Hep G2 cells. Cells were grown, and LDL receptors were upregulated by incubation in lipoprotein-deficient serum as described in METHODS. VLDL from E4/4 and E3/3 subjects were added to cells in duplicate at apolipoprotein B (apoB) concentrations shown, together with 10 µg/ml of 125 I-LDL (E3/3), and were incubated for 2 h at 4°C. Cells were washed extensively in albumincontaining buffers before being solubilized in NaOH and counted for radioactivity in a gamma counter. Results are means of duplicate measurements Ϯ SD and are for the second E4/4, E3/3 pair of http://ajpendo.physiology.org/ VLDL was more effective than E3/3 VLDL in competing for the LDL receptor, the IC 50 ratio being significantly lower than unity (0.73 Ϯ 0.31, P Ͻ 0.05). IC 50 values themselves were marginally lower in E4/4 than E3/3 subjects (3.7 Ϯ 1.3 vs. 6.1 Ϯ 3.7, P Ͻ 0.08). These significance values would change to P Ͻ 0.02 and P Ͻ 0.05, respectively, with one-tailed t-tests based on our initial hypothesis. In contrast to results on Hep G2 cells, the data do not support a difference in the affinity of E4/4 and E3/3 VLDL for the LDL receptors on fibroblasts.
The composition of the VLDLs used in these binding studies is shown in Table 3 . There was no significant difference in the lipid composition of VLDL from the E4/4 and E3/3 subjects and no relationship between the triglyceride or cholesterol content, or triglyceride-tocholesterol ratio, of the VLDLs and their corresponding IC 50 values or IC 50 ratios for studies in either cell type.
Competitive studies on LDL from E3/3 and E4/4 subjects were also carried out, and the results are presented in Table 4 . In summary, those results showed that there was not a significant difference between the affinity of LDL particles from E4/4 and E3/3 subjects in either Hep G2 cells or fibroblasts. To determine whether the method of preparation of LDL could have affected receptor affinity and abolished an E isoform-dependent effect, we compared LDL to homologous VFP in ability to compete against 125 I-LDL for receptor binding. The results, summarized in Table 5 , showed that there was no difference between the IC 50 values of these two preparations in fibroblasts. In Hep G2 cells, VFP was marginally a better competitor than LDL, but there was no difference between E4/4 and E3/3 subjects.
DISCUSSION
The important new finding is that inheritance of the E4 isoform is associated with an increased affinity of VLDL particles for the LDL receptor on cultured liver cells. It has previously been shown that apoE can mediate the binding of large VLDL [Svedberg units (S f Ͼ 100)] from hypertriglyceridemic subjects and small VLDL (S f range 20-60) from normal subjects to the LDL receptor (7, 10) . We found that VLDL from normal subjects competes against LDL for binding to high-affinity binding sites, that is, specifically the binding to LDL receptors. On the basis of the competitive binding studies, we also found that homozygosity for the E4 isoform increased the affinity of the VLDL of the subject for the LDL receptor on Hep G2 cells. The binding of VLDL was expressed relative to apoB to reflect affinity in terms of lipoprotein particle numbers because each VLDL particle contains only a single apoB molecule. VLDL apoE was not quantitated, and the http://ajpendo.physiology.org/ increased affinity of VLDL from E4 homozygous subjects may be due to the extra positive charge conferred by arginine at amino acid 112 in apoE4 (26) or to apoE content. Concerning other VLDL components, there was no significant difference in the triglyceride or cholesterol content of VLDL from the E4/4 and E3/3 subjects, and there was no correlation between the triglyceride or cholesterol content, or triglyceride-tocholesterol ratio, of the VLDLs and the binding results.
There are few studies in the literature with approaches comparable to ours. Recently, Bohnet et al. (5) , studying direct binding, showed that the affinity of 125 I-labeled VLDL for Hep G2 cells was higher for VLDL from subjects without an E2 allele (E4/4, E4/3, E3/3) than those with an E2 allele. However, no difference could be discerned, after adjustment for apoB content as in our study, between the affinities of VLDL from E4/4, E4/3, or E3/3 subjects. This contrasts with the competitive binding studies presented here, which were used in preference to direct binding studies because they permit comparison of relatively unaltered VLDLs, whereas direct binding studies require the use of harsh reagents, such as iodine-monochloride, and exposure to a strong radiation source ( 125 I), which has been shown to change lipoprotein composition and cell binding (19) . Indeed, in direct binding studies on the VLDL of six E4/4 and six E3/3 subjects (not shown), we also did not find any difference in affinity between E4/4 and E3/3 subjects in binding to Hep G2 cells at 4°C (K d values: 22 Ϯ 11 vs. 21 Ϯ 10 nM, respectively). A further advantage of the competition studies is that they allow comparison of VLDLs in their ability to inhibit highaffinity binding of 125 I-LDL to LDL receptors; that is, the binding studied is specifically that to LDL receptors, whereas, conceptually, direct binding of VLDL may also reflect binding to other VLDL or apoE receptors. That the binding of 125 I-LDL was specific for the LDL receptor is based on the following considerations. First, binding of 125 I-LDL to the cells could be downregulated by incubation of the cells in LDL-containing nutrient medium, that is, medium containing unmodified fetal calf serum instead of lipoprotein-depleted fetal calf serum (data not shown). Second, the binding was of high affinity and yielded Scatchard plots consistent with the presence of one major binding site for LDL. In addition, whereas other receptors, such as the scavenger receptor, are thought capable of binding oxidized or chemically modified LDL, the LDL receptor is the only receptor yet described capable of binding unmodified LDL.
In contrast to our competitive binding results on Hep G2 cells, there was little difference between the affinity of E4/4 and E3/3 VLDL for the LDL receptor of cultured fibroblasts. This may be related to differences in binding characteristics between the LDL receptor of fibroblasts and of Hep G2 cells because differences between these cells have been clearly documented. For example, the LDL receptor on Hep G2 cells and on liver membranes has a lower affinity for LDL than that on fibroblasts, as reported by us and others (15, 21, 24) . Furthermore, whereas the uptake of hypertriglyceridemic LDL by cultured fibroblasts was found to be lower than that of normal LDL, the reverse was observed for Hep G2 cells (23) .
Few studies have examined the role of apoE in binding of LDL to the LDL receptor, possibly because the concentration of apoE in LDL is low. However, Chappell et al. (6) showed that apoE mediates the binding of large LDL to the LDL receptor, and indirect evidence from the study of a subject homozygous for the apoB Arg 3500 =Gln mutation suggests that apoE can mediate LDL binding (22) . There is also evidence of Gregg and Brewer (12) found a lower plasma clearance rate for the LDL of E2 homozygotes, and a preliminary report by Arnold et al. (1) suggests that LDL from E2/2 subjects binds with lower affinity to the LDL receptor. We did not find a difference in binding affinity of LDL from E4/4 and E3/3 subjects, and the concordant result on VFP, comprised primarily of LDL as the major LDL-receptor binding species, suggests that this was not due to an artifact produced by LDL isolation.
However, that the E4 isoform increases binding of VLDL to the LDL receptors of hepatocytes has implications for the metabolism of LDL as well as for VLDL. The elevated LDL plasma concentration of E4/4 subjects has been related by Demant et al. (8) to increased production and decreased catabolism; it was postulated that the latter may be related to the increased intestinal cholesterol absorption (18) and chylomicron remnant clearance in E4/4 subjects (25), which, by increasing the hepatic cholesterol pool, downregulates LDL-receptor expression and hence hepatic receptormediated clearance of LDL (8) . Perhaps increased delivery of lipids by E4/4 VLDL also augments the hepatic cholesterol pool. Additionally, VLDL may retard hepatic uptake of LDL more in E4/4 subjects by greater competition with LDL for uptake.
In conclusion, homozygosity for apoE4 increases binding of VLDL to LDL receptors on cultured hepatic cells; this might partly explain the variations in lipoprotein metabolism and the propensity to atherosclerosis associated with the E4 genotype.
